학술논문
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
Document Type
Article
Author
Source
In: The Lancet Oncology . (The Lancet Oncology, June 2020, 21(6):763-775)
Subject
Language
English
ISSN
14745488
14702045
14702045